Hideaki Yamakawa

Contemporary Guideline Perspectives on Methotrexate and Biologic/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation that affects the patient outcomes. Published guidelines and consensus documents on RA-ILD or systemic autoimmune rheumatic disease/connective tissue disease-associated ILD have updated drug selection for RA-ILD; howev...